Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories


Ventus Therapeutics executes $100m series B
RA Capital has led a $100m series B round for Ventus Therapeutics, which is linked to multiple universities.
Icosavax racks up $100m
RA Capital Management has led a series B round for the UW-linked vaccine developer, which had raised $51m in a series A 18 months ago.
Pyxis Oncology advances to $152m series B
The cancer treatment developer, co-founded by researchers from University of Chicago, has secured funding in a round co-led by Arix Bioscience and RTW Investments.
Omega sanctions $126m series C round
The developer of epigenetic medicine, based on Whitehead Institute research, pulled in funding through a round led by founding investor Flagship Pioneering.
Entrada enters series B stage
Ohio State University spinout Entrada Therapeutics has pocketed $116m in a series B round.
Gyroscope turns to CIC for $148m
Cambridge Innovation Capital has returned for a series C round for University of Cambridge-linked Gyroscope Therapeutics, which also welcomed back Syncona.
Evidation Health leverages corporates to raise $153m
Evidation, co-founded by Stanford University and GE Ventures, has picked up series E funding at a $1bn valuation.
ActionIQ gets series C extension done
ActionIQ has pushed its series C round to $100m following an extension from existing shareholders.

Other News

Inflammatix invites series D investors
D1 Capital Partners has led a $102m series D round for Inflammatix, whose existing shareholders include Stanford-StartX Fund.
Vaccitech gets $168m series B injection
The spinout’s technology was fundamental to Oxford’s covid vaccine, prompting OSI and Future Planet Capital to back a $168m round.
Graphite Bio assembles $150m series B
RA Capital Management and Rock Springs Capital have co-led a series B round for the gene editing technology developer spun out of Stanford six months ago.
Century Therapeutics sells Bayer on $160m round
Versant Ventures, which incubated the cell-based immunotherapy developer based on Harvard and Stanford research, has backed a $160m round.
Caribou clinches $115m series C
UC Berkeley-founded genome editing technology developer Caribou Biosciences has completed its first funding round in five years.
Exscientia expands series C to $100m
BlackRock has joined the University of Dundee spinout’s series C round, following a $60m first close in May last year.

Editor's Picks

Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Immunocore smashes European biotech records
Immunotherapy firm Immunocore, which started life at Oxford University, raises the largest biotech round in European history.
test reg